13.18
1.20%
-0.16
Handel nachbörslich:
13.38
0.20
+1.52%
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Revenues |
23.36%
141.01
|
183.98 | 153.64 | 146.82 | 134.28 |
Cost Of Revenue |
29.48%
48.09
|
68.20 | 58.12 | 47.21 | 35.90 |
Gross Profit |
19.75%
92.91
|
115.78 | 95.53 | 99.61 | 98.39 |
Operating Expenses
|
9.68%
154.41
|
170.97 | 190.32 | 162.97 | 150.38 |
Interest Income/Expense |
87.50%
0.001
|
0.008 | 0.001 | 0.005 | 0.019 |
Benefits Costs and Expenses |
13.78%
198.81
|
230.58 | 245.39 | 207.59 | 183.94 |
Costs And Expenses |
13.78%
198.81
|
230.58 | 245.39 | 207.59 | 183.94 |
Operating Income/Loss |
11.43%
-61.50
|
-55.19 | -94.80 | -63.36 | -51.99 |
Nonoperating Income/Loss |
56.98%
3.695
|
8.59 | 3.051 | 2.591 | 2.334 |
Income/Loss From Continuing Operations Before Tax |
24.05%
-57.80
|
-46.60 | -91.74 | -60.77 | -49.65 |
Income Tax Expense/Benefit |
8.84%
2.146
|
2.354 | 1.242 | 1.647 | 1.093 |
Income/Loss From Continuing Operations After Tax |
22.46%
-59.95
|
-48.95 | -92.99 | -62.41 | -50.75 |
Net Income/Loss
|
22.46%
-59.95
|
-48.95 | -92.99 | -62.41 | -50.75 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
25,194%
119.39
|
0.472 | 117.73 | 116.71 | 115.62 |
Diluted Average Shares |
25,194%
119.39
|
0.472 | 117.73 | 116.71 | 115.62 |
Basic Earnings Per Share |
21.95%
-0.50
|
-0.41 | -0.79 | -0.53 | -0.44 |
Diluted Earnings Per Share |
21.95%
-0.50
|
-0.41 | -0.79 | -0.53 | -0.44 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):